Michael Grövdal

DNA methylation arrays as surrogate measures of cell mixture distribution

Cancer Epigenetics: From Mechanism to Therapy

Epigenetic responses following maternal dietary exposure to physiologically relevant levels of bisphenol A

TET enzymes, TDG and the dynamics of DNA demethylation

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells

Therapy with azanucleosides for myelodysplastic syndromes

Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin

EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals

Semi-supervised recursively partitioned mixture models for identifying cancer subtypes

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome

Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science

Multiple Myeloma

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

Maintenance treatment with azacytidine for patients with high‐risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome